Ozelle

What Ozelle does

Ozelle (Ozelle GmbH) is a Germany-based medical device company that develops and manufactures AI-powered hematology analyzers for human and veterinary diagnostics. The company was founded in 2014 in Silicon Valley by postdoctoral researchers from institutions including Lawrence Berkeley National Laboratory, the California Department of Public Health, McMaster University, and the U.S. National Academy of Sciences, and relocated R&D operations to Frankfurt during the COVID-19 pandemic. Its core product line consists of the EHBT-75, EHBT-50, and EHBT-25 analyzers for human clinical use and the EHVT-75 and EHVT-50 for veterinary practice, all built around the proprietary AI × CBM (Complete Blood Morphology) technology that pairs high-resolution cell imaging with morphology-based diagnostic interpretation.

The diagnostic platform processes up to 60 tests per hour standalone (360 tests/hour via cascade expansion in the O-Cyte 1 high-throughput system) and is unified by the Intelligent AI Workbench (OpenDx), which provides conversational AI report interpretation, anomaly detection, risk stratification, and scenario-ready panels for infection profiling, disease management, and malaria screening. The system has been trained on a corpus described as 100+ billion real-world cellular data points drawn from 50,000+ global installations generating 50 million cell images daily, and holds CE, FDA, ISO 13485:2016, and ISO 9001 certifications. Manufacturing is anchored in Changsha, China, with reagent and consumable supply creating a recurring revenue stream alongside hardware sales.

Ozelle generates revenue through one-time/perpetual hardware sales of analyzers, ongoing reagent and consumable sales, and software delivered through the AI Workbench. The go-to-market combines direct enterprise sales to hospitals, laboratories, and clinics via structured inquiry and demo workflows, distributor and importer partnerships for regional expansion, and event-driven marketing through major industry conferences (ADLM 2026, WHX Labs Dubai 2026). Commercial operations span offices in Frankfurt (R&D), Abu Dhabi (Middle East sales), Shenzhen (regional marketing), and Changsha (manufacturing), with active market development across North America, Europe, the Middle East, Southeast Asia, and India. Ownership remains founder-controlled under Chairman and Founder Shuang Hu, with no disclosed institutional funding rounds.

Name

Ozelle

Legal name

Ozelle GmbH

Website

https://ozellemed.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Ozelle (Ozelle GmbH) is a Germany-headquartered medical device company that develops AI-powered hematology analyzers and diagnostic software for hospitals, laboratories, clinics, and veterinary practices worldwide, with 50,000+ global installations and a unified AI Workbench platform.

Ownership category

akta.pro rank

Product category

In Vitro Hematology Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hematology & Coagulation Diagnostics (HLAHAAAB)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

Keywords

• AI hematology analyzers
• Complete blood morphology
• Veterinary diagnostic analyzers
• In vitro diagnostics
• Clinical decision support software

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Hematology Analyzers: Sale of automated hematology analyzers including EHBT-75, EHBT-50, EHBT-25 for human use and EHVT-75, EHVT-50 for veterinary use. One-time hardware purchase model with modular, scalable systems.
2. Reagents and Consumables: Ongoing sale of reagents for hematology analysis systems, supporting continuous use of analyzer equipment.
3. AI Workbench Software: AI-powered diagnostic interpretation and analysis software integrated into clinical workflows, potentially offered as part of system packages or standalone subscriptions.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Ozelle manufactures and sells AI-powered automated hematology analyzers for human clinical diagnostics (EHBT-75, EHBT-50, EHBT-25) and veterinary diagnostics (EHVT-75, EHVT-50), along with the O-Cyte 1 high-throughput analyzer. The hardware is paired with the AI Workbench (OpenDx) software platform, which delivers AI-driven Complete Blood Morphology analysis, conversational report interpretation, risk stratification, and clinical decision support, supported by proprietary reagents and consumables.

Product overview

Ozelle offers a comprehensive portfolio of AI-powered hematology diagnostic solutions consisting of automated analyzers and an integrated software platform. The human health product line includes the EHBT-75 (auto hematology analyzer), EHBT-50 (mini lab multi-functional analyzer combining hematology, biochemistry, and immunoassay), and EHBT-25 (cell morphology analyzer). The veterinary line includes EHVT-75 and EHVT-50 multi-functional analyzers. The recently launched O-Cyte 1 brings high-throughput capability (60-360 tests/hour) with AI × CBM technology. All hardware products are unified through the Intelligent AI Workbench (OpenDx) software platform, which provides AI-powered report interpretation, risk stratification, and clinical decision support across the diagnostic portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• OpenDx: AI Workbench platform that integrates test ordering, result review, and AI-assisted interpretation into a single workflow for both human and veterinary diagnostics.

Products and services

• EHBT-75 Auto Hematology Analyzer Automated hematology analyzer for human clinical diagnostics. Next-generation system designed for high-throughput laboratory settings requiring comprehensive blood analysis with AI-powered morphology integration.
• EHBT-50 Mini Lab Multi-Functional Analyzer All-in-one AI diagnostic system combining hematology, biochemistry, and immunoassay testing in a compact form factor. Designed as an intelligent diagnostic pipeline within clinical settings, capable of handling most routine tests efficiently.
• EHBT-25 Cell Morphology Hematology Analyzer Cell morphology hematology analyzer focused on AI-powered blood cell analysis. First clinical application of Ozelle's morphology AI technology, enabling expert-level morphological examination at point-of-care settings.
• EHVT-75 Multi-Functional Analyzer for Vet Next-generation veterinary hematology analyzer with multi-functional diagnostic capabilities. Supports efficient workflows in veterinary practice with automated blood analysis and AI-assisted interpretation.
• EHVT-50 Multi-Functional Analyzer for Vet Veterinary multi-functional analyzer enabling integrated diagnostics for animal healthcare. Supports efficient workflows in everyday veterinary care with comprehensive blood testing capabilities.
• O-Cyte 1 Automated Hematology Analyzer Automated hematology analyzer with AI-powered morphology intelligence. Processes up to 60 tests per hour standalone and up to 360 tests per hour through cascaded expansion. Designed for clinical settings requiring high-throughput hematology workflows with morphology analysis integration.
• Intelligent AI Workbench (OpenDx) Unified clinical intelligence platform integrating diagnostic results with AI-powered interpretation. Features include report overview with risk stratification, clinical risk alerts, conversational AI report interpretation, anomaly detection, automated risk stratification, and follow-up insights with trend analysis. Available for both human and veterinary diagnostics.
• Hematology Analyzer Reagents Reagent consumables for Ozelle hematology analyzers. Supports the complete diagnostic workflow with optimized reagents for consistent analysis performance.

Quantifiable outcome

• Up to 360 tests per hour with cascade expansion (60 tests/hour standalone)
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• ADLM 2026 ConferencecoreGTM or Marketing Partner · 29 June 2026Ozelle debuted O-Cyte 1 at ADLM 2026 in Anaheim, California - a major global launch at one of the leading international diagnostics and laboratory medicine trade shows, marking significant market expansion.
• WHX Labs Dubai 2026 ExhibitioncoreGTM or Marketing Partner · 10 February 2026Ozelle showcased AI-powered diagnostic solutions at WHX Labs Dubai 2026 (February 10-13), seeking distribution partnerships and regional deployment discussions. Key marketing and partnership development event for Middle East expansion.
• NirmidasminorStrategic or Co-development Partner · 1 November 2014Research cooperation initiated in November 2014 focused on Personal and Portable Health Diagnostic Testing. This was an early-stage partnership in the company's founding period.
• StartX (Stanford's Accelerator)minorStrategic or Co-development Partner · 1 November 2014Research cooperation focused on Personal and Portable Health Diagnostic Testing, leveraging Stanford's accelerator ecosystem for healthcare innovation.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Beckman Coulter (Danaher): Major hematology analyzer vendor within Danaher's diagnostics platform, with significant US hospital penetration. Competes with Ozelle in clinical hematology and is actively adding AI/digital morphology features to its DxH series.
• Siemens Healthineers: Large diversified diagnostics vendor with Atellica hematology analyzers. Broad incumbent with overlapping capabilities and a global sales footprint that materially exceeds Ozelle's.
• Abbott: Diversified IVD player with CELL-DYN hematology analyzers and Alinity series. Operates broadly in clinical diagnostics and competes with Ozelle in hospital hematology channels.
• Sysmex: Global market leader in hematology analyzers with deep installed base across hospitals and reference labs. Directly competes with Ozelle's EHBT and O-Cyte 1 products but serves a broader IVD portfolio and larger enterprise customers.

Direct peers

• Mindray: Chinese-headquartered IVD company offering BC-7000/7500 series hematology analyzers with growing global share. Closely comparable in target segments, price tiers, and emerging-market focus.
• Boule Diagnostics: Smaller specialty hematology and veterinary diagnostics vendor. Comparable in product scope (human + vet analyzers) and in competing for mid-market and emerging-market customers.
• Scopio Labs: AI-driven digital morphology and cell imaging company focused on hematology. Directly comparable technology approach to Ozelle's AI × CBM platform, targeting laboratories seeking AI-augmented blood cell analysis.
• CellaVision (BD): Pioneer in digital cell morphology for hematology, now part of BD. Competes directly in the AI-enabled peripheral blood smear analysis category that Ozelle's morphology AI addresses.
• Horiba Medical: Specialized hematology analyzer manufacturer offering the Yumizen series. Comparable mid-sized vendor competing for clinical lab and mid-tier hospital customers globally.

Emerging players

• Sight Diagnostics: AI-powered blood analysis company with FDA-cleared OLO device for point-of-care complete blood count. Comparable in combining AI with hematology diagnostics and targeting decentralized testing settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC9aRrEh8r7gb3iX3vPvbHGw
• Facebookfacebook.com/people/Ozelle/61554405117096
• LinkedInlinkedin.com/company/ozellegmbh

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ozelle